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An amyloid fibril protein (MA) was purified as a 17,OOO-dal-
ton protein from a case of nodular primary cutaneous amy-
loidosis, and its partial amino acid sequence (22 residues from 
N-terminal) was determined. A. sequence closely homolo-
gous to that of the A. III subgroup of the immunoglobulin 
light chain was detected. This is the third case of nodular 
N odular primary cutaneous amyloidosis is such a rare type of amyloidosis that fewer than 50 cases, in-cluding 13 Japanese cases (1), have been reported in the world literature [2,3). This disease is character-ized clinically by ovoid, shiny, pink-yellow nod-
ules or plaques with a glossy and atrophic appearance (1), which 
may be located on the skin of any site of the body, and histologically 
by extensive deposits of amyloid in the papillary and reticular 
dermis [2,3) . The origin of this type of amyloid has not yet been 
clarified, although there are now increasing numbers of cases in 
which the immunoglobulins are thought to be of a light-chain 
origin, as studied by immunofluorescence microscopy using anti-
AL (amyloid proteins related to light chain of immunoglobulin) 
antibodies [1,3-5). Two amyloid fibril proteins have been isolated 
from amyloid tumors of two patients with nodular cutaneous amy-
loidosis, and partial amino acid sequences have been derived. The 
fib ril proteins have been revealed to be of the K III and the A I 
subgroups of immunoglobulin light chains, respectively [4,5). 
In the present study, the partial amino acid sequence (22 residues 
from N-terminal) of an amyloid fibril protein from a case of nodular 
primary cutaneous amyloidosis was determined, and it was shown to 
be closely homologous to that of the A III subgroup of the immuno-
globulin light chain. 
MATERIALS AND METHODS 
Source of Cutaneous Amyloid Fibrils Amyloidotic tissues 
(amyloid tumors) were obtained from a 63-year-old woman who, 
over a ten-year period, had many firm nodules on the trunk and 
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primary cutaneous amyloidosis which has been studied at the 
level of sequence analysis of purified amyloid fibril proteins, 
and the first case of nodular primary cutaneous amyloidosis in 
which a A. III amyloid protein has been shown to be present by 
sequence analysis. ] Invest Dermatol 95:301- 303) 1990 
lower extremities, ranging in size from approximately 1 to 5 cm in 
diameter. No amyloid deposits were detected in gastric and rectal 
mucosal membranes, although an elevated IgG level of2204mg/dl 
and the presence of M protein (monoclonal IgG-A, 10.7% of total 
protein, 8.2 g/ dl) were noted. No Bence Jones proteins were de-
tected in urine even after it was concentrated 100 times. 
Because no symptoms other than skin nodules had been noticed 
for more than 10 years, and no amyloid deposits had been detected 
in any sites of the body other than the skin even by extensive exami-
nations, nodular primary cutaneous amyloidosis was diagnosed for 
the present case. However, the possibility that systemic amyloidosis 
might develop in the future could not be excluded because of M-
protein in the serum. 
Besides cutaneous amyloidosis, the patient also has Sjogren's syn-
drome, with positive titers ofSS-A antibody (1: 16), SS-B antibody 
(1: I), and antinuclear antibody (1: 20). The clinical and histopath-
ologic data of this case have been described in detail in a previous 
paper (6) . 
Extraction and Purification of Amyloid Fibril Proteins Ex-
traction of amyloid fibrils was performed by the methods ofPras et 
al [7) and Glenner and co-workers [8 ,9). The excised amyloid 
tumors (5 .5 g wet weight) were separated from the epidermis by a 
scalpel, cut into small pieces, and homogenized in physiologic sa-
line (110 ml) using a glass homogenizor. The homogenate was 
sonicated for 15 s and centrifuged at 12,000 X g at 4 0 C for 30 min. 
This washing procedure was repeated several times until the absorb-
ance of the supernatant at 280 nm became less than 0.05. The final 
precipitate was resuspended, homogenized, and sonicated in 110 ml 
of distilled water. The homogenate was centrifuged at 12,000 X g 
at 4 0 C for 30 min. The first supernatant was discarded and the 
second to fifth supernatants were collected, combined (400 ml in 
total) , and lyophilized. This preparation, which showed straight 
fibrils 8 to 10 nm in diameter on electron microscopy, was com-
posed of a main protein with molecular weight of 17 kDa, and 
minor component proteins with molecular weights of 20 kDa 
and 29 kDa. These results were precisely described in the previous 
paper [6). 
The amyloid fibril preparation (MA) thus obtained was further 
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purified as follows: the !yophilized .crJ:stallines (1 mg) were sus-
pended in water conratnl11g 5 mM dlthlOthreltol, dialyzed agalllst 
1 I of water containing 0.01 111M dithiothreitol for 2 d at room 
temperature, and the dialysate was centrifuged at 100,000 rpm for 
20 min. The resulting supernatant was then subjected to high-per-
formance liquid chromatography (HPLC) using a reversed phase 
column (Waters libondasphere C4, 5 Ii, 30DA). A D.l % trifluoro-
acetic acid/water (solvent A) and 0.1 % trifluoroacetic acid/acetoni-
tril (solvent B) gradient system was used . Elution was performed 
isocratically with solvent A for 5 min, followed by a linear gradient 
from 0 to 100% so lvent B for 60 min. The flow rate was one 
ml/min and the column effluent was monitored by absorbances at 
both 215 nm and 280 nm. The relevant protein peaks were col-
lected and concentrated by a vacuum concentrator. 
Amino Acid-Sequence Analysis The amino acid sequence of 
the purified amy loid was determined by a gas-phase protein sequen-
ator, Model 470A, connected to a Model 12DA PTH-Amino Acid 
Analyzer (Applied Biosystems, Foster City, CA). 
RESULTS 
In our previous study [6], it was shown that the amyloid protein 
(MA) consisting of the major 17-kDa protein and the minor 20-kDa 
and 29-kDa proteins revealed a fibrillar structure under electron 
microscopy which was characteristic of amyloid fibrils. These amy-
loid proteins had a peculiar nature: the Iyophylized preparation was 
almost insoluble in aqueous so lution containing any kind of salt, 
including chaotropic ions and/or sodium dodecyl sulfate. Organic 
solvents such as alcohols, acetonitri le, and other water-miscible sol-
vents also failed to solubilize the proteins. Finally we found that an 
extensive dialysis against water in the presence oflow concentration 
of the reducing agent dithiothreitol successfully solubilized the 
amyloid proteins. It then became possible to purify them further 
using a reversed-phase HPLC. In Fig 1, a typical elution profile is 
presented. A main protein peak collected in fractions 37 and 38 
consisted of the major 17 -kDa protem when subjected to SDS-
PAGE (data not shown). 
The purified 17 -kDa protein was subjected to amino acid se-
quencing as described in Materials and Methods. The amino acid 
sequence of the N-terminal 22 residues determined is shown in 
Table 1, and is compared with those of Bence Jones proteins and 
amyloid-associated Bence Jones proteins of the A-type. This com-
parison indicated that the N-terminal 22 residues of this protein 
have a sequence closely homologous to the A III light chain. 
Figure 1. HPLC elution profile of amyloid proteil1S. The solu-
bilized amyloid proteins (0.8 mg) were injected onto a pbon~-
3sphere column at 0 min, and the proteins were eluted Isocran-
cal ly with solvent A (0.1% trifluoroacetic acid/water) for 5 min, 
followed by a linear gradient from 0 to 100% solvent B (0.1 % 
trilluoroacetic acid/acetonitril) ill 60 min. The flow rate was 1 
ml / min and the column effluent was monitored by absorbances at 
both 215 and 280 nm. The scale indicates absorbanccs of 0.1 for 
215 nm and 0.01 for 280 11m, respectively. 
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DISCUSSION 
The human A light chain has been divided into six subgroups (A I, ~ 
II, A III, A IV, A V, and A VI) on the basis of the characteristic aminl:l 
acid sequence occurring within the first framework region (FRl) 
[11 J. The FR 1 consists of the N -terminal 23 residues of the variabl~ 
region of the li ght chain. The sequence of the N-terminal region ° 
the 17-kDa protein of the present case revealed 86% homology tl:l 
that of subgroup III, and 82% to that of subgroup IV of the A light 
chain of immunoglobulin, and less than 60% to the four othet 
subgroups. However, the invariant residues (residues underlined ~ 
Table I) characteristic for subgroup A III showed a complete coinci, 
dence with the corresponding residues of the 17 -kDa protein., 
whereas the invariant residues for subgroup A IV sh')wed a substitu, 
tion of tyrosine for serine at the second position of the N-terminal 
on the 17-kDa protein. This finding may suggest that this amyloict 
protein could be classified as subgroup A III, although it also shows, 
close homology to subgroup A. IV. 
Of these subgroups, subgroup A VI has been shown to be most 
commonly found in association with primary systemic or myeloma, 
associated amyloidosis [12-14], and, more recently, subgroups .A.I,~ 
11 and A III were found, although much less frequently , in amyloid, 
associated light chains [10,15). 
With regard to the frequency of occurrence of individual sub.. 
groups of A light chains and associated amyloidosis, Solomon et al 
l13) studied 97 A-type Bence Jones proteins by serologic analys~ 
using antibodies against individual subgroups. The percentage of ~ 
I, A II + Y, A III, A. IV and A VI proteins were found to be 26, 38, 22, 
3, and 11%, respectively. Twenty proteins of those 97 were asso, 
cia ted with amyloidosis, and 11 were classified as A VI, seven as ~ 
II + A Y, and two as A III . As shown in their studies, only two of21 
cases of A III Bence Jones proteins were associated with amyloidosis, 
It is of interest to note that A III amyloid was found in the present 
case of nodular cutaneous amyloidosis. 
o 
Although all of the A VI proteins were associated with amyloi, 
dosis [13], the findings that other subgroups of A. light chains al 
have been found in primary or myeloma-associated amyloidos~ 
suggests that the amyloidogenicity of the paraprotein cannot alwa~,\ 
be explained by the sequence specificity of the subgroups of th~ 
li ght chain. This is further supported by the fact that the sequence 0 
MA differed largely (only 55% homology) from that of A VI, whi~ 
has been shown to be the most amy loidogenic of light chain para, 
proteins [12). 
The molecular weight of the amyloid fibril proteins of light 
chains is usually lower than that of intact li gh t chains of immuno-, 
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Table I. Comparison of Amino Acid Sequence for the First 23 Amino Acids (Framework Region 1) of the Amyloid Fibril Protein, 
MA and Those of Six A. Human Light Chain Subgroups· 
MA 
). Chain 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Homology 
Subgroupb IY!: Ala Val Thr GIn Pro Pro Ser Val Ser Val Ser Pro Q!y GIn Thr Ala Arg lie Thr ~ % 
..lI PCA' Ser Val Leu Thr GIn Pro Pro Ser Val Ser Gly Ala Pro Q!y Gly Arg Val Thr lie ala ala thr Ser ~ 50 
). II PCA Scr Ala Lcu Thr GIn Pro Aln Ser Va l Ser Q!y Ser Pro Q!y Gly Ser lie Thr lie arg/pro ala val Ser Cys 55 
). III Ser' IY!: Glu Leu Thr GIn Pro Pro Ser Val Ser Val Ser Pro Q!y GIn Thr Ala Arg ~ Thr Cys val ala Ser 86 
). IV Ser Glu Leu Thr GIn Pro Pro Ser Val Ser Val Ala Pro Gly GIn Thr Val Arg lie Thr ~ asp ser leu ala 82 
..lV PCA Ser Ala Leu Thr GIn Pro Pro Ser Ala Ser Q!y Ser Pro Q!y GIn Ser Val Thr ~ Ser ~ 59 
..l VI Asn phe Met Leu Thr GIn Pro His Ser Val Ser Glu Ser Pro Q!y Lys Thr Val Thr lie Ser Cys 55 ~ 
'The amino acid residue occurring exclusively or most often at the designated position is shown capitalized; the next most common residue is indicated in lower case (sequence data 
from [13J and [11]). V"derli"e, invariant residues for individual subgroups. 
' For comparison of K and..l chain FRI sequences, a gap is introduced between positions 9 and 11 [11, 13J. 
'PCA represents pyrrolidine-carboxylic acid. 
'This residue is deleted in some ..l III chains. 
globulin (23 kDa). This difference is mainly attributed to the ab-
sence of a part of the C-terminal constant region [1 6J. In this regard, 
it was shown in our previous paper [6] that anti-A. monoclonal anti-
body (clone C4, Cosmo Bio, Tokyo, Japan) did not bind to the 
amyloid protein MA. However, a co-purified trace component with 
a molecular weight of 29 kDa did bind to the antibody, when 
studied by immunoblotting [6]. This suggests that the present amy-
loid protein also lacks some portion of the C-terminal constant 
region. 
Although a preferential association of A. I with the localized nodu-
lar form of amyloidosis has been reported [14], the present case may 
suggest that this association is not always true. It is hard to relate the 
amino acid sequence of paraproteins to amyloidogenicity at the 
present time. 
Concerning primary nodular cutaneous amyloidosis, only three 
cases, including the present case, have been studied at the level of the 
amino acid sequence. Because the purification of amyloid proteins 
from nodular cutaneous amyloidosis appears to be much easier than 
those from other forms of cutaneous amyloidosis, the study of amy-
loid at the sequence level should be done in future, so that some 
clues may be obtained to understanding the mechanism of preferen-
tial amyloid deposition in the skin. 
We thallk Dr. S. M. Breatil/lQch, Reader alld COllsultallt Derlllatologist ofC/wrillg 
Cross alld Westmillster Medical School, Ulliversity of LOlldon, for reviewillg the 
manuscript. 
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